P-199 Baseline neutrophil to lymphocyte ratio predicts survival in patients with metastatic colorectal cancer treated with cetuximab plus avelumab (CAVE) as a rechallenge strategy

Authors :: Pietro Paolo Vitiello
Giulia Martini
Filippo Pietrantonio
Davide Ciardiello
Lucia Esposito
M. Terminiello
Teresa Troiani
Giuseppe Santabarbara
Daniele Santini
A. Di Liello
Evaristo Maiello
Nicola Normanno
Carmine Pinto
C. Cremolini
Fortunato Ciardiello
Salvatore Napolitano
Erika Martinelli
A. Avallone
Vincenzo Famiglietti
Tiziana Latiano
C. Borrelli
Source :: Annals of Oncology. 32:S167-S168
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Oncology
medicine.medical_specialty
Cetuximab
Colorectal cancer
business.industry
Hematology
medicine.disease
Avelumab
Internal medicine
medicine
In patient
Neutrophil to lymphocyte ratio
business
medicine.drug

Full Text Access

Tools